Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 9/20 | 0.47 |
| ▸ | RET | P07949 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.47 |
| ▸ | PRKACA | P17612 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.47 |
| ▸ | GSK3A | P49840 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740145 | 0.65 | NOS3 (0.39) | KDRROCK1AURKAAURKB | |
| SCHEMBL968490 | 0.64 | DYRK1A (1.00) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL3979845 | 0.64 | LIMK1 (0.48) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL6163081 | 0.62 | PI4KA (0.36) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL6461918 | 0.61 | EGFR (0.49) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL31026187 | 0.61 | EGFR (0.49) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL5426668 | 0.58 | SELE (0.65) | LMNA | |
| SCHEMBL3388247 | 0.58 | MEN1 (0.44) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL4801961 | 0.58 | LIMK1 (0.42) | LIMK1RETKDRMAP4K4LRRK2 | |
| SCHEMBL2838236 | 0.58 | PIP4K2A (0.46) | LIMK1RETKDRMAP4K4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | UCK2, AXL, CHUK | LIMK1 368/4885RET 284/4885KDR 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.